Trial Profile
Study of prognostic factors associated with postprogression survival (PPS) in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 30 Aug 2018 New trial record